medigraphic.com

2015, Number 2

<< Back Next >>

Rev Cuba Endoc 2015; 26 (2)

Association between testosterone levels, insulin sensitivity, adiposity and lipid parameters in men

Álvarez ÁA, Marrero FMÁ, Gónzalez SRM, Perich AP, Arranz CMC, Domínguez AE, Chapé PA, Sánchez LS, Rodríguez AJ

Language: Spanish
References: 49
Page: 124-137
PDF size: 194.51 Kb.


ABSTRACT

Introduction: evidence suggests that testosterone participates in the regulation of glucose and lipid metabolism.
Objective: determine the relationship between testosterone levels and insulin sensitivity, adiposity and metabolism parameters in men.
Methods: a descriptive cross-sectional study was conducted of 225 men aged 35-60 with and without glucose tolerance disorders. The variables measured were height, weight, and waist and hip circumference. Determinations were made for insulin, glycemia, testosterone, cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Insulin sensitivity and resistance were also determined.
Results: a negative correlation was found between testosterone levels/insulin resistance and the adiposity parameters considered (body mass index, waist and hip circumference and waist to hip ratio). Testosterone levels were lower in subjects with hypertriglyceridemia. Patients with tolerance disorders showed a significant increase in the frequency of abdominal obesity in the presence of low testosterone values.
Conclusions: a direct relationship was found between testosterone levels and insulin sensitivity in the population studied. Reduced testosterone levels in the presence of disorders associated to metabolic syndrome suggest the need for an early metabolic assessment of patients with hypogonadism.


REFERENCES

  1. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008;11(4):193-9.

  2. Jones TH. Clinical physiology of testosterone. Testosterone deficiency in men. New York: Oxford University Press Inc.; 2008. p. 9-21.

  3. Álvarez A, Díaz E, Huguez B, González RM. Glucemia, insulinemia y secreción de insulina en ratas hipoandrogenizadas e hiperandrogénicas. Rev Cubana Endocrinol. 1999;10(2):133-9.

  4. Álvarez A, Díaz E, Castells EM, Huguez B, González RM. Glucemia, insulinemia y secreción de insulina en ratas prepúberes hiperandrogenizadas e hiperestrogenizadas. Rev Cubana Endocrinol. 2001;12(1):15-21.

  5. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R, Walker BR. Deletion on the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes. 2012;61(5):1072-81.

  6. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance, influence of sex hormonebinding globulin and body fat. Diabetes Care. 2004;27:861-8.

  7. Kupelian V, Hayes FJ, Link CL, Rosen R, McKinlay JB. Inverse Association of Testosterone and the Metabolic Syndrome in Men is Consistent across Race and Ethnic Groups. Journal of Clinical Endocrinology & Metabolism. 2008;93:3403-10.

  8. Pitteloud N, Hardin M, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Increasing insulin resistance is associated with a decrease in Leyding cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90:2636-41.

  9. Madalena CH, Stella V, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. Review article. J Cell Physiol. 2012;227(2):3744-8.

  10. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34:528-40.

  11. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES 2 study). Diabetes Care. 2011;34:828-37.

  12. Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol. 2009;114(1-2):40-3.

  13. Laaksonen DE, Niskanen L, Punnonen K, Nyysonen K, Tuomanen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036-41.

  14. Khaw KT, Chir MBB, Dowsett M, Folkerd E, Binghan SH, Wareham N, et al. Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men. American Heart Association. 2007;116:2694-701.

  15. Singh SK, Goyal R, Pratyush DD. Is hypoandrogenemia a component of metabolic syndrome in males? Exp Clin Endocrinol Diabetes. 2011;119:30-5.

  16. Ding ER, Song Y, Malik V, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. JAMA. 2006;295:1288-99.

  17. Singh AB, Hsia S, Alaupovic P. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136-43.

  18. Singh R, Artaza JN, Taylor WE, González-Cadavid NT, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated patway. Endocrinology. 2003;144:5081-8.

  19. Álvarez A, González RM, Marrero MA. Papel de la testosterona y el cortisol en el síndrome metabólico y la diabetes tipo 2. Rev Cubana Endocrinol. 2010;21(1):80-90.

  20. Rao PT, Kelly DM, Jones TH. Testosterone and insulin resistance in metabolic syndrome and T2DM in men. Nature Reviews Endocrinology. 2013;9:479-93.

  21. Wang CH, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669-75.

  22. WHO. Diabetes Mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of the Diabetes Mellitus. World Health Organization Department of Non-communicable Disease Surveillance. Geneva; 1999.

  23. Barham D, Trinder P. Glucosa GOD-PAP. Analyst. 1972;97:142-5.

  24. Schettler G, Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  25. Schettler G, Nüssel E. Triglycerides liquicolor GPO-PAP. Arb Med Loz Med Präv Med. 1975;10:35.

  26. Lópes-Virella M, Stone MF, Ellis S. Cholesterol determinations in HDL separated by three different methods. Clin Chem. 1977;23:882-5.

  27. Díaz Sánchez ME. Manual de Antropometría para el Trabajo de Nutrición. La Habana: Instituto de Nutrición e Higiene de los Alimentos; 1992. p. 13-4.

  28. IDF. Clinical Guidelines Task Force. Global Guidelines for type 2 Diabetes: recommendations for standard, comprehensive, minimal care. Diabetic Medicine. 2006;23:579-93.

  29. Matthews DR, Husker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and Beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.

  30. Arranz C, Rodríguez B, Álvarez Á, Reyes A, de Dios R, González R. Valores de referencia para el índice de resistencia a la insulina del modelo homeostático (RIHOMA) estimado a partir de los resultados de una muestra mixta hospitalaria. Revista de la Asociación Latinoamericana de Diabetes. 2007;XV:121.

  31. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab. 1998;63:134-41.

  32. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

  33. Álvarez A, Arranz C, Marrero MA, González RM, Perich P, Chapé A, et al. Valores de referencia para el Cortisol, Testosterona y del índice Cortisol/Testosterona en sujetos con tolerancia a la glucosa normal. Revista de la Asociación Latinoamericana de Diabetes. 2007;XV(3):120.

  34. Kapoor D, Aldrech H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavaible testosterone and visceral adiposity. Diabetes Care. 2007;30:911-7.

  35. Van Pottelberg I, Braeckman L, De Bacquer D, De Bacquer G, Kaufman JM. Differential contribution of testosterone and estradiol determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003;166:95- 102.

  36. Stanworth RD, Kapoor D, Channer KS, Jones TH. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clin Endocrinol. 2011;74:624-30.

  37. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63:280-93.

  38. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, Jansin H, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296:1051-7.

  39. Hofstra J, Loves S, van Wageningen B, Ruinemans-Koerts J, Janssen I, de Boer H. High prevalence of hypogonadotropic hypogonadism in men refered for obesity treatment. Neth J Med. 2008;66:103-9.

  40. Smith MR, Lee H, Natham DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;9:1305-8.

  41. Kapoor D, Goodwin E, Channer E, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906.

  42. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272-83.

  43. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology. 2005;30:1-10.

  44. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85:1310-40.

  45. Pasquali R, Vicennati V, Gambineri A, Pagotto U. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. International Journal of Obesity. 2008;32:1764-79.

  46. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496-506.

  47. Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovascular Diabetology. 2009;8:44.

  48. Yialamas MA, Dwyer AA, Hanley E. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinolol Metab. 2007;92:4254-9.

  49. Ibebunjo C, Eash JK, Li C, Ma Q, Glass DJ. Voluntary running, skeletal muscle gene expression, and signalling inversely regulated by orchidectomy and testosterone replacement. Am J Physiol Endocrinol Metab. 2011;300:E327-E340.




2020     |     www.medigraphic.com